Skip to main content
. 2024 Oct 10;11(4):573–591. doi: 10.1007/s40801-024-00459-6

Table 2.

Baseline characteristics—switched population

Switched patientsa Rheumatology cohort Gastroenterology cohort
RA
N = 39
PsA
N = 30
AS
N = 119
CD
N = 108
UC
N = 14
Data capturing, n (%)
 Fully prospective 30 (76.9%) 21 (70.0%) 82 (68.9%) 72 (66.7%) 11 (78.6%)
 Shifted prospective 2 (5.1%) 2 (6.7%) 7 (5.9%) 14 (13.0%) 2 (14.3%)
 Fully retrospective 7 (17.9%) 7 (23.3%) 30 (25.2%) 22 (20.4%) 1 (7.1%)
Age, years, mean (SD) 60.7 (12.2) 52.8 (13.6) 48.0 (13.3) 43.0 (14.3) 37.9 (11.7)
Female patients, n (%) 30 (76.9%) 11 (36.7%) 45 (37.8%) 44 (40.7%) 5 (35.7%)
Weight, kg, mean (SD) 68.3 (12.7) 80.4 (16.7) 76.1 (16.4) 75.2 (17.7) 73.0 (19.1)
Height, cm, mean (SD) 163.8 (9.4) 170.8 (8.3) 169.8 (9.7) 170.9 (8.9) 171.1 (9.5)
BMI, kg/m2, mean (SD) 25.4 (4.5) 27.7 (5.6) 26.5 (5.7) 25.7 (5.3) 24.7 (5.2)
Disease duration, years, mean (SD) 20.3 (12.4) 11.4 (8.2) 14.3 (12.4) 12.9 (9.3) 9.6 (7.8)
Patients with comorbidities at baseline, n (%)A 20 (51.3%) 17 (56.7%) 58 (48.7%) 42 (38.9%) 3 (21.4%)
Patients with co-treatments at baseline, n (%)A 23 (59.0%) 8 (26.7%) 10 (8.4%) 20 (18.5%) 2 (14.3%)
Prior adalimumab, n (%)
 Reference adalimumab only 37 (94.9%) 29 (96.7%) 113 (95.0%) 103 (95.4%) 13 (92.9%)
 Biosimilar adalimumab only 0 (0.0%) 1 (3.3%) 3 (2.5%) 2 (1.9%) 0 (0.0%)
 Reference and biosimilar adalimumab 2 (5.1%) 0 (0.0%) 3 (2.5%) 3 (2.7%) 1 (7.1%)
Prior exposure to other biologics, n (%)
 Infliximab 1 (2.6%) 3 (10.0%) 5 (4.2%) 19 (17.6%) 3 (21.4%)
 Etanercept 2 (5.1%) 3 (10.0%) 14 (11.8%) 1 (0.9%)
 Ustekinumab 1 (0.9%)
 Golimumab 1 (3.3%)
 Certolizumab pegol 1 (2.6%) 2 (6.7%) 2 (1.7%)
 Tocilizumab 1 (2.6%)
 Secukinumab 1 (0.8%)
 JAK inhibitors 1 (2.6%)
Patients taking methotrexate at baseline, n (%) 18 (46.2%) 6 (20.0%) 6 (5.0%) 5 (4.6%)
Patients taking azathioprine at baseline, n (%) 8 (7.4%)
Number of patients with disease activity scores at baseline, n (%)

DAS28-ESR

14 (35.9%)

DAS28-CRP

5 (12.8%)

BASDAI

8 (26.7%)

DAS28-ESR

3 (10.0%)

DAS28-CRP

4 (13.3%)

BASDAI

57 (47.9%)

HBI

81 (75.0%)

SCCAI

8 (57.1%)

Categorical disease activity scores, n (%)
 Remission 15 (78.9%) 3 (20.0%) N/A 68 (84.0%) N/A
 Low/mild disease activity 9 (60.0%) 36 (63.2%) 7 (8.6%) 8 (100%)
 Moderate disease activity 3 (15.8%) 2 (13.3%) N/A 6 (7.4%) N/A
Data capturing, n (%)
Fully prospective 30 (76.9%) 21 (70.0%) 82 (68.9%) 72 (66.7%) 11 (78.6%)
 High disease activity 1 (5.3%) 1 (6.7%) 21 (36.8%)

AS ankylosing spondylitis, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, CD Crohn’s disease, CRP C-reactive protein, DAS28 Disease Activity Score (28 joint), ESR erythrocyte sedimentation rate, HBI Harvey–Bradshaw Index, N/A not applicable, PsA psoriatic arthritis, RA rheumatoid arthritis, SD standard deviation, SCCAI Simple Clinical Colitis Activity Index, shifted prospective part prospective/part retrospective, UC ulcerative colitis

aBoth from reference and from biosimilar adalimumab

AFull listings of comorbidities and co-treatments reported at baseline are provided in Supplementary Tables S3A & S3B

HHS Vulnerability Disclosure